Article Text

PDF

032
SEE NO EVIL, HEAR NO EVIL, SPEAK NO EVIL… KEEP IT A SICRET
  1. Ruth Dobson1,
  2. Anisha Doshi1,
  3. Luke Massey2,
  4. Louise Crowe1,
  5. Ruth Wood1,
  6. Sriram Vundavalli1,
  7. Ed Hughes3,
  8. Mike Lunn2,
  9. Gordon Plant2,
  10. Mirdhu Wickremaratchi1
  1. 1Hurstwood Park Neurosciences Centre
  2. 2National Hospital for Neurology and Neurosurgery
  3. 3Royal Sussex County Hospital

Abstract

A 21-year-old presented with a one-month history of confusion and headache, with collateral history suggestive of focal seizures. Examination revealed an encephalopathic patient with a bilateral internuclear ophthalmoplegia and a spastic ataxic quadraparesis. MRI demonstrated multiple non-enhancing hyperintense T2 lesions in the cerebellum, corpus callosum, grey and white matter, some with restricted diffusion. There was marked posterior fossa leptomeningeal enhancement. CSF protein was 2.32g, with 5 lymphocytes and negative oligoclonal bands. Brain biopsy showed non-specific inflammatory changes.

Extensive infective, inflammatory and malignancy screening was negative. Despite an initial clinical response to a steroid pulse, new lesions developed, accompanied by clinical deterioration.

Two months into the illness, whilst on high-dose oral steroids, he developed characteristic branch retinal artery occlusions. A diagnosis of Susac's syndrome was made, despite normal audiometry. Treatment with aggressive immunosuppression was successful.

Susac's (‘small infarctions of cochlear, retinal and encephalic tissue’ (SICRET)) syndrome, is a rare, presumed autoimmune, endotheliopathy. Microvascular occlusions lead to the pathognomonic triad of encephalopathy, sensorineural deafness and branch retinal artery occlusions, rarely all present at presentation. Seizures are an unusual feature. Temporal dispersion of symptoms may delay diagnosis for months in some patients. A literature review of clinical features and treatment will be presented.

  • EPILEPSY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.